Valuation : EyePoint, Inc.

Market Cap 395M 340M 320M 292M 546M 37.28B 548M 3.78B 1.47B 19.13B 1.48B 1.45B 61.62B P/E 2026 *
-1.25x
P/E 2027 * -1.75x
Enterprise Value 72.06M 62.01M 58.34M 53.29M 99.7M 6.8B 99.97M 689M 268M 3.49B 271M 265M 11.25B EV / Sales 2026 *
41.9x
EV / Sales 2027 * 4.49x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : EyePoint, Inc.

1 day+0.33%
1 week+2.23%
Current month+1.78%
1 month-64.30%
3 months-61.12%
6 months-70.92%
Current year-74.93%
1 week 4.32
Extreme 4.325
4.92
1 month 3.95
Extreme 3.95
14.76
Current year 3.95
Extreme 3.95
18.87
1 year 3.95
Extreme 3.95
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Others

Chief Financial Officer

-139,906 0.1669%
18/8/26 Buy

Director

10,600 0.0126%
10/7/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%+2.23%-67.31%-53.12% 395M
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
+0.14%-0.47%+30.20%+41.44% 352B
-1.33%+4.72%+24.62%+48.58% 304B
-1.15%+0.30%-0.69%+13.20% 252B
-1.55%+1.11%+54.15%+75.59% 236B
-0.88%+1.15%-14.60%-54.96% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.81%+1.36%+19.06%+42.97% 367.88B
Weighted average by Cap. -0.96%+0.62%+37.62%+68.00%

Financials

2026 *2027 *
Net sales 1.72M 1.48M 1.39M 1.27M 2.38M 162M 2.39M 16.46M 6.39M 83.34M 6.46M 6.32M 268M 17.92M 15.42M 14.51M 13.25M 24.8M 1.69B 24.86M 171M 66.53M 868M 67.3M 65.83M 2.8B
Net income -344M -296M -279M -255M -476M -32.49B -477M -3.29B -1.28B -16.67B -1.29B -1.26B -53.7B -287M -247M -232M -212M -396M -27.05B -398M -2.74B -1.06B -13.88B -1.08B -1.05B -44.72B
Net Debt -323M -278M -261M -239M -447M -30.48B -448M -3.09B -1.2B -15.64B -1.21B -1.19B -50.37B -314M -271M -255M -233M -435M -29.69B -436M -3.01B -1.17B -15.23B -1.18B -1.16B -49.07B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
04/09/26 USD 4.580 +0.33% 1,901,886
03/09/26 USD 4.565 -4.70% 2,625,997
02/09/26 USD 4.790 +4.59% 4,716,139
01/09/26 USD 4.580 +1.78% 3,261,201
31/08/26 USD 4.500 +0.45% 3,506,365
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
4.580USD
Average target price
25.91USD
Spread / Average Target
+465.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!